Key points
- Revenue of $114.5m with a 3% increase YoY
- EBITDA of $10.9m with a 19% increase YoY
- Expanded manufacturing capacity by over 40% in two years
Full summary
SomnoMed Ltd reported its FY26 full-year results for the period ended 30 June 2026. The company reported revenue of $114.5 million, up 3% on the previous corresponding period (pcp), and EBITDA of $10.9 million, up 19% in FY26. The company expanded its manufacturing capacity by over 20% during FY26 and over 40% across the last two years, while improving operational efficiency and reducing production times by over 50% across the same period. The company maintained a robust net cash position of $16.8 million at 30 June 2026, enabling support of future growth initiatives.
Guidance
High single digit revenue growth in FY27 while maintaining EBITDA margins consistent with FY26
Outlook
SomnoMed is targeting a return to double-digit revenue growth while progressively expanding EBITDA margins through scale and efficiency gains.